求翻译：急性脑梗死给人类和社会造成了十分巨大的危害。我国脑卒中(其中约75 %为脑梗死) 每年新发病例约150 万,患病人数高达500 万～600 万,每年死亡者近100 万,存活者中约1/ 4 不同程度地丧失劳动力,重度致残者占40 %以上。因此,脑梗死的防治一直是我们面临的一个主要课题。1995 年美国国立神经疾患与脑卒中研究院(NINDS)进行了脑梗死发病3 h 以内,静脉用重组组织型纤维蛋白溶酶原激活剂( rt-PA) 的大规模临床试验,证明了rt-PA 的有效性[ 1 ]。我院自2009年起对22例患者进行了急诊静脉溶栓，取得了良好效果，汇报如下：是什么意思？

Acute cerebral infarction causing very great harm to the human and society. Stroke (which some 75% for cerebral infarction) about 1.5 million new cases each year, the number as high as 5 million ~600 million, nearly 1 million deaths each year, about one-fourth different degree invalidity in survivors, more than 40% with severe disabilities. Therefore, prevention and treatment of cerebral infarction has been is that we face a major task. 1995 United States National Institute of neurological disorders and stroke (NINDS) to cerebral infarction within 3 h, intravenous recombinant tissue-type fiber protein plasminogen activator (rt-PA) for large scale clinical trials, proof of the effectiveness of rt-PA [1]. From 2009 on 22 patients in our hospital conducted emergency Thrombolysis, and achieved good results, reported as follows: